Humacyte Stock Performance
| HUMA Stock | USD 1.06 -0.10 -8.62% |
Humacyte has a performance score of 1 on a scale of 0 to 100. The company owns a Beta (Systematic Risk) of 2.3, which signifies a somewhat significant risk relative to the market. Humacyte tends to amplify market moves - gaining more in rallies but giving back more during declines. Humacyte right now owns a risk of 6.59%. Please confirm Humacyte the relationship between the skewness and day typical price.
Risk-Adjusted Performance
Soft
Weak | Strong |
Across the last 90 days, the risk-adjusted return profile of Humacyte is weaker than 1% of the global equities and portfolios reviewed by Macroaxis. Used properly, the ranking helps separate absolute gains from efficient gains. Despite somewhat uncertain primary indicators, Humacyte may actually be approaching a critical reversion point that can send shares even higher in April 2026. Learn More
1 | Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications | 01/08/2026 |
2 | Acquisition by Dale Sander of 20000 shares of Humacyte at 1.53 subject to Rule 16 b-3 | 01/09/2026 |
3 | While institutions invested in Humacyte, Inc. benefited from last weeks 10 percent gain, retail investors stood to gain the most | 01/12/2026 |
4 | Humacyte Given New 10.00 Price Target at Benchmark - Market Beat | 01/21/2026 |
5 | Humacyte, Inc. Receives 8.14 Average Target Price from Analysts | 01/26/2026 |
6 | Humacyte, Inc. Stock Analysis Biotechnology Innovator with a 648 percent Potential Upside - Directors Talk Interviews | 01/30/2026 |
7 | Humacyte Valuation Check As Do D Funding Highlights Battlefield Vascular Repair Potential | 02/10/2026 |
8 | Humacyte, Inc. Receives Average Recommendation of Moderate Buy from Analysts - Market Beat | 02/17/2026 |
9 | Humacyte, Inc. Is Considered a Good Investment by Brokers Is That True - Yahoo Finance | 03/06/2026 |
10 | Disposition of 389 shares by Dale Sander of Humacyte at 2.56 subject to Rule 16 b-3 | 03/16/2026 |
11 | Humacyte Submits Marketing Authorization Application for Symvess in Israel for Vascular Trauma Repair | 03/17/2026 |
| Begin Period Cash Flow | 80.8 M | |
| Total Cashflows From Investing Activities | -1.6 M |
Humacyte | Build portfolio with Humacyte Stock |
Relative Risk vs. Return Landscape
If you had invested $ 111.00 in Humacyte on December 18, 2025 and sold it today you would have lost $ 5.00 from holding Humacyte or given up 4.5% of portfolio value over 90 days. Humacyte is currently generating a 0.1256% daily expected return and carries 6.5894% risk (volatility on return distribution) over a 90-day horizon. In different words, 59% of stocks are less volatile than Humacyte, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
Prices of stocks like Humacyte Stock tend to oscillate around a central value over time, a phenomenon known as mean reversion. Although this tendency is a useful forecasting input, some instruments remain persistently underpriced or overpriced before the market corrects the discrepancy.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 1.06 | 90 days | 1.06 | about 63.97 |
Under a normal probability framework, the likelihood of Humacyte moving above the current price in 90 days from now is about 63.97 (The distribution above models the probability of Humacyte Stock reaching different price points within 90 days).
Humacyte Price Density |
| Price |
Predictive Modules for Humacyte
The challenge of forecasting Humacyte mirrors the broader difficulty of predicting stock market movements. No single technique offers reliable accuracy, but investors who apply multiple methods and compare the results are better positioned to identify potential outcomes and manage risk effectively.While mean reversion in Humacyte is a statistically observable tendency, it operates on uncertain timelines. Positions sized too aggressively against the trend can suffer sustained losses before reversion occurs.
Primary Risk Indicators
The stock market has been marked by significant volatility in the last 10-20 years, and Humacyte has not been spared. Both sharp declines and strong rallies have tested investor discipline. A hedging strategy built around Humacyte's risk indicators can help those holding Humacyte manage downside risk more effectively.α | Alpha over Dow Jones | 0.07 | |
β | Beta against Dow Jones | 2.30 | |
σ | Overall volatility | 0.08 | |
Ir | Information ratio | -0.0071 |
Investor Alerts and Insights
Investors who use alerts for Humacyte can respond more quickly to important stock events. Notifications for Humacyte highlight significant technical and fundamental shifts that may create new opportunities or signal emerging risks.| Humacyte had very high historical volatility over the last 90 days | |
| Humacyte has some characteristics of a very speculative penny stock | |
| Humacyte has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was -148.7 M with loss before overhead, payroll, taxes, and interest of -73.8 M. | |
| Humacyte currently holds about 189.04 M in cash with -98.12 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Humacyte Submits Marketing Authorization Application for Symvess in Israel for Vascular Trauma Repair |
Price Density Drivers
Humacyte price dynamics are shaped by the balance between buyer and seller activity. When short interest rises or long traders begin reducing positions, volatility tends to increase. Key market indicators are shown below.
| Common Stock Shares Outstanding | 118.5 M | |
| Cash And Short Term Investments | 44.9 M |
Humacyte Fundamentals Growth
Investor sentiment toward Humacyte Stock is largely driven by Humacyte's fundamental metrics. Revenue growth rates, earnings per share trends, profit margin changes, and leverage ratios are among the most impactful factors determining Humacyte Stock market behavior.
| Return On Equity | -2.5 | |||
| Return On Asset | -0.63 | |||
| Operating Margin | -32.39 % | |||
| Current Valuation | 234.21 M | |||
| Shares Outstanding | 193 M | |||
| Price To Earning | 18.04 X | |||
| Price To Book | 57.77 X | |||
| Price To Sales | 142.51 X | |||
| Gross Profit | -73.8 M | |||
| EBITDA | -132.23 M | |||
| Net Income | -148.7 M | |||
| Cash And Equivalents | 189.04 M | |||
| Cash Per Share | 1.84 X | |||
| Total Debt | 16.54 M | |||
| Debt To Equity | 0.36 % | |||
| Current Ratio | 17.46 X | |||
| Book Value Per Share | -0.03 X | |||
| Cash Flow From Operations | -98.12 M | |||
| Earnings Per Share | -0.27 X | |||
| Market Capitalization | 223.88 M | |||
| Total Asset | 137.87 M | |||
| Retained Earnings | -686.01 M | |||
| Working Capital | 27.91 M | |||
Performance Metrics & Calculation Methodology
Humacyte performance is measured on a risk-adjusted basis against benchmarks. Benchmark comparison clarifies whether outcomes reflect exposure or implementation effects. Humacyte shows ROE of -2.5%, ROA of -63.44%.
Data shown for Humacyte is aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Source publication cadence can introduce delays. Return and risk statistics are calculated from historical price series.